Over the last few years, Curetis has created a down-to-earth and continuous success story. It all began with the Unyvero product idea and progressed through the development and approval procedure towards tapping into the international medical technology markets. From the outset, the company has impressed with its high awareness of quality combined with a strong pioneering spirit and the simple claim: "We care for diagnostics". This success was due, in no small part, to the outstanding engineering capabilities and molecular and microbiological expertise of both our investors and our customers and partners.
Curetis' growth potential lies, on the one hand, in developing and expanding the world's national markets and, on the other hand, in extending the Unyvero system with a continuous stream of new cartridges for additional infectious diseases.
Subscribe to Curetis Newsletter
Curetis Publishes Business and Financial Update for the First Quarter 2018
Curetis to Hold Annual General Shareholders’ Meeting on June 21, 2018
ATS - American Thoracic Society 2018 - San Diego, USA - May 20 to 22, 2018
ASM - Microbe 2018 - Alanta, USA - June 8 to 10, 2018